Skip to main content
Medical information Clinical review pending

Genetic Testing

SLC39A13 Gene Spondylocheirodysplasia Ehlers-Danlos Syndrome-like Genetic Test

Genetic test to identify mutations in the SLC39A13 gene associated with spondylocheirodysplasia and Ehlers-Danlos syndrome-like conditions.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube) or Saliva sample. Confirm specific requirements with the laboratory before booking.
Results
Confirm with the laboratory before booking.
Preparation
No special preparation is typically required for this test. However, confirm with the laboratory for any specific instructions.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the SLC39A13 Gene Spondylocheirodysplasia Ehlers-Danlos Syndrome-like Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Symptoms suggestive of spondylocheirodysplasia
  • ✓Symptoms suggestive of Ehlers-Danlos syndrome-like conditions
  • ✓Joint hypermobility
  • ✓Skin elasticity issues
  • ✓Bone deformities
  • ✓Family history of related genetic disorders
  • ✓Chronic pain associated with connective tissue or bone disorders
02

In plain language

What this test helps you understand

This test helps identify specific genetic mutations in the SLC39A13 gene, which can confirm a diagnosis of spondylocheirodysplasia or related Ehlers-Danlos syndrome-like conditions. It aids in understanding the genetic basis of the condition, which can inform prognosis, management strategies, and genetic counseling for the patient and their family.
The SLC39A13 Gene Spondylocheirodysplasia Ehlers-Danlos Syndrome-like NGS Genetic DNA Test is a diagnostic tool used to detect mutations in the SLC39A13 gene. These mutations are linked to rare genetic disorders affecting bone and connective tissue development, such as spondylocheirodysplasia and conditions resembling Ehlers-Danlos syndrome. This test uses Next Generation Sequencing (NGS) technology for accurate results. Understanding the genetic basis of these conditions is important for patient management and family planning. This test can help identify the underlying cause of specific clinical presentations.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is typically required for this test. However, confirm with the laboratory for any specific instructions.
SampleBlood sample (EDTA tube) or Saliva sample. Confirm specific requirements with the laboratory before booking.
MethodologyNext Generation Sequencing (NGS) of the SLC39A13 gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test analyzes specific regions of the SLC39A13 gene. It may not detect all possible mutations, such as large deletions or duplications, or mutations in other genes that could cause similar symptoms. A negative result does not completely rule out a genetic disorder. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

The SLC39A13 gene provides instructions for making a protein involved in the development and maintenance of bone and connective tissue.
These are rare genetic disorders affecting the skeleton, joints, and connective tissues. Symptoms can vary but often include bone deformities, joint problems, and skin changes.
Individuals experiencing symptoms like joint hypermobility, skin elasticity issues, bone deformities, or chronic pain, especially with a family history of similar conditions, may be candidates for this test.
Results are interpreted by genetic specialists. You will receive guidance on the implications of the findings, including potential risks for family members and management options.
Insurance coverage varies. Please check with your insurance provider regarding coverage for genetic testing.
You can book the test by contacting the laboratory directly via phone or WhatsApp at +254711564616.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp